



Quest Diagnostics Announces Pricing in Offering of Common Stock by the Company's Largest Shareholder

February 1, 2011

MADISON, N.J., Feb. 1, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced the pricing of the previously announced secondary public offering of 15,377,600 shares of Quest Diagnostics common stock held by its largest stockholder, SB Holdings Capital Inc., an affiliate of GlaxoSmithKline plc ("GSK") at a price to the public of \$56.25.

Quest Diagnostics has not sold any shares of common stock in the offering and will not receive any of the proceeds from the sale of shares in the offering.

Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are joint bookrunners for the offering.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. A written prospectus for this offering meeting the requirements of Section 10 of the Securities Act of 1933 (other than a free writing prospectus as defined in Securities Act Rule 405) may be obtained from Deutsche Bank Securities Inc., 100 Plaza One, Jersey City, N.J. 07311 or by calling 1-800-503-4611, or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 1-866-803-9204.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Contacts for Quest Diagnostics: Kathleen Valentine (Investors), +1-973-520-2900, or Gary Samuels, (Media), +1-973-520-2800

SOURCE Quest Diagnostics Incorporated